What is HC Wainwright’s Estimate for CLDX FY2025 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a research report issued to clients and investors on Wednesday, November 20th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn ($2.99) per share for the year, up from their previous forecast of ($3.02). HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.45) per share.

CLDX has been the subject of several other reports. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $27.02 on Friday. The firm’s 50 day moving average price is $30.21 and its 200-day moving average price is $34.92. Celldex Therapeutics has a 52-week low of $22.93 and a 52-week high of $53.18. The company has a market cap of $1.79 billion, a PE ratio of -10.51 and a beta of 1.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CLDX. KBC Group NV increased its stake in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics in the second quarter worth $76,000. CANADA LIFE ASSURANCE Co increased its position in Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares during the period. Finally, Quest Partners LLC lifted its holdings in shares of Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 6,879 shares during the last quarter.

Insider Buying and Selling

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the company’s stock in a transaction on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 3.80% of the stock is owned by insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.